The Pipeline

Our two clinical-stage product candidates, Inupadenant (EOS-850) and EOS-448, each target a key mechanism that inhibits an effective antitumor immune response: the ATP adenosine pathway and a novel checkpoint TIGIT, respectively. We believe that both product candidates have the potential to further increase patient responses to standard cancer therapies, including immunotherapy. We are evaluating numerous biomarkers in our clinical programs to maximize this potential through choosing synergistic combination agents and identifying patients most likely to benefit from our product candidates. 

We are also using our deep understanding of the critical immune resistance pathways to identify new targets and generate additional differentiated programs for underexploited pathways validated by a strong scientific rationale.